Endocare — Merger or Acquisition (January 2009)
21 slides from Endocare's merger presentation, Jan 14, 2009
Slide 1: A Strategic Combination to Advance Cryoablation
A Strategic Combination to Advance Cryoablation The Merger of Endocare (NASDAQ:ENDO) and Galil Medical January 13, 2009
Slide 2: Forward Looking Statements
2 Forward Looking Statements Certain matters set forth in this presentation, including statements relating to the merger, such as efficiencies, cost savings, enhanced revenues and EBITDA, the timing of such cost savings and enhanced revenues and EBITDA, growth potential, market profile and financial
Slide 3: Combined Company Profile
3 Combined Company Profile Headquarters Irvine, CA Board composition 9 directors - 4 from each prior board, 1 new independent Leadership Marty Emerson, CEO Michael Rodriguez, CFO Capital Infusion $16.25 private placement
Slide 4: Galil Medical Overview
4 Galil Medical Overview Privately held cryoablation company - Yoqneam, Israel Major stockholders include Thomas McNerney & Partners, The Vertical Group, Investor Growth Capital, Elron and RDC TTM revenues of $25.0M, gross profit of $17.9M 120+ employees in 4 countries Strong international sales pre
Slide 5: Strategic Drivers for Combined Company
Strategic Drivers for Combined Company Develop robust data sets for current and new indications Deliver new technologies Systems and disposables Current and new indications Drive penetration of cryoablation solutions based on: Better understanding of patient and physician requirements Effective resp
Slide 6: Economic Rationale Behind Merger
6 Economic Rationale Behind Merger Improve platform to penetrate broader market for cryoablation Leverage existing sales and distribution Eliminate duplicate selling and administrative costs Eliminate redundant clinical trials and studies
Slide 7: Current Cryoablation Procedures: 2008 Estimated U.S. Cancer Cases
7 Men 745,180 Women 692,000 Prostate 25% Lung & bronchus 15% Colon & rectum 10% Urinary bladder 7% Melanoma of skin 5% Non-Hodgkin's 5% lymphoma Kidney 4% Leukemia 3% Oral cavity 3% Pancreas 3% All other sites 20% 26% Breast 14% Lung & bronchus 10% Colon & rectum 6% Uterine corpus 4% Melanoma of ski
Slide 8: Strong Cryoablation Opportunity
8 Strong Cryoablation Opportunity Significant clinical advantages Current cryoablation technology has fewer side-effects than radiation Rapid emergence of focal technology Best practices policy statement on cryoablation adopted by AUA Superior economics Healthcare system prefers overall lower cost o
Slide 9: U.S. Prostate Cancer Market - 2008
9 Prostate Cancer U.S. Prostate Cancer Market - 2008 500+ Men Today will be Diagnosed with Prostate Cancer Current Annual Treatments(2) (2)Internal Endocare estimate 80,000 59,000 9,000 17,000 21,000 (1)American Cancer Society - Cancer Facts & Figures 2008 (3)Includes estimated cases from Endocare &
Slide 10: U.S. Kidney Tumor Market - 2008
10 U.S. Kidney Tumor Market - 2008 100+ People Today will be Diagnosed with Renal Cancer Renal Cancer (1)American Cancer Society - Cancer Facts & Figures 2008 (2)Internal Endocare estimate Current Annual Treatments(2) Addressable market composed of: Lesions <5cm U.S. Annual Occurrence(1) 54,000 Addr
Slide 11: Compelling Physician Economics
11 Compelling Physician Economics Robotic Radical Prostatectomy Brachytherapy Cryoablation Brachytherapy with IMRT Radical Prostatectomy $1,715 $1,117 $1,300 $741 $741 Robotic Radical Prostatectomy Radical Prostatectomy Cryoablation Brachytherapy with IMRT $520 $490 $494 $558 $494 Brachytherapy Appr
Slide 12: "Best of Breed" Cryoablation Products
12 Systems Single Use Disposables "Best of Breed" Cryoablation Products
Slide 13: Operational Strengths
13 Operational Strengths Experienced senior management Strong financial team Manufacturing scale Increased efficiency of corporate functions Finance, legal, HR Customer service, sales Marketing, manufacturing Clinical, regulatory & R&D
Slide 14: Marketplace Efficiency
14 Marketplace Efficiency Strong focus on cryoablation demand and awareness Worldwide market reach Large customer base Solid penetration among physicians and hospitals Seasoned sales team (domestic and international) Efficient marketing - trade shows, web, education Experienced R&D team (cryoablatio
Slide 15: Transaction Overview
15 Transaction Overview Transactions Stock-for-stock merger of Endocare and Galil Medical, concurrent $16.25M PIPE Exchange ratio 52% Endocare / 48% Galil Medical Pro forma shares 39.0M including PIPE @$1.00/share Anticipated close Late Q1 to Q2 2009, subject to approvals Approvals Endocare stockhol
Slide 16: Opportunity for Efficiencies
Opportunity for Efficiencies Anticipated to be $10+ Million Primary savings opportunities - near term Overlapping sales territories Redundant marketing programs Surplus facilities Duplicative senior management Repetitive G&A functions Similar clinical and regulatory programs Primary savings opportun
Slide 17: Pro Forma Financial Highlights
17 17 Pro Forma Financial Highlights Pro forma trailing twelve month figures as of 9/30/08: Revenue $55.6M Gross profit $39.1M Adjusted EBITDA(1) anticipated to be positive within 18 months of closing $10M+ of annual synergies $16.25M financing expected to be a bridge to profitability (1)EBITDA less
Slide 18: Steps to Closing
18 Steps to Closing Proxy statement/prospectus to be filed Proxy statement/prospectus to be mailed to stockholders Israeli and U.S. regulatory reviews Endocare stockholder meeting to approve transaction expected March 2009 Closing expected late Q1 to Q2 2009
Slide 19: Summary
Summary Growth company driving enhanced shareholder value Poised for meaningful revenue & profit growth Substantial operating cost, interest & tax savings Expanded worldwide distribution Highly regarded brands Complementary IP portfolio Strong balance sheet Greater combined innovative potential 19
Slide 20: Additional Information About the Merger
20 In connection with the proposed merger with Galil Medical, Ltd. ("Galil"), Endocare, Inc. ("Endocare") intends to file a registration statement on Form S-4 (the "Registration Statement"), which will also include a proxy statement of Endocare, and other relevant documents concerning the transactio
Slide 21: A Strategic Combination to Advance Cryoablation
A Strategic Combination to Advance Cryoablation The Merger of Endocare (NASDAQ:ENDO) and Galil Medical January 13, 2009